Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy

Zhang,Zhu‑Hong; Chen,Qing‑Zhong; Jiang,Feng; Townsend,Todd  A.; Mao,Chun‑Jie; You,Cai‑Yun; Yang,Wen‑Hui; Sun,Zhi‑Yong; Yu,Jin‑Guo; Yan,Hua

doi:10.3892/mmr.2016.6048

Changes in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy

Authors:
- Zhu‑Hong Zhang
- Qing‑Zhong Chen
- Feng Jiang
- Todd A. Townsend
- Chun‑Jie Mao
- Cai‑Yun You
- Wen‑Hui Yang
- Zhi‑Yong Sun
- Jin‑Guo Yu
- Hua Yan
View Affiliations

Affiliations: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Division of Genetic and Molecular Toxicology, US Food and Drug Administration, National Center for Toxicological Research, Jefferson, AR 72079, USA
Published online on: December 14, 2016 https://doi.org/10.3892/mmr.2016.6048
Pages: 573-580
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor (TNF) ligand related molecule 1A (TL1A), also termed TNF superfamily member 15 and vascular endothelial growth inhibitor is important for tumorigenicity and autoimmunity. However, the function of TL1A in diabetic retinopathy (DR) remains to be elucidated. The present study established a diabetes mellitus (DM) rat model to investigate TL1A, vascular endothelial growth factor (VEGF), tumor necrosis factor‑α (TNF‑α) and interleukin‑1β (IL‑1β) expression levels in the retina, vitreous and serum of rats with DM at different stages (1 month group, 3 month group and 6 month group). The present study determined that TL1A expression levels in the retina and vitreous from the DM 1 month group were significantly lower compared with the control group. However, TL1A levels in the retina and vitreous were significantly increased in advanced stages of DM compared with the control group. Furthermore, the levels of VEGF in the retina and vitreous were significantly higher in the DM groups compared with the control group. The expression levels of TNF‑α and IL‑1β in the retina and vitreous were significantly higher in DM 3 month and 6 month groups compared with the control group. It is of note that the expression levels of TL1A were significantly lower in the DM 1 and 3 month groups compared with the control group; however, they were significantly increased in the DM 6 month group compared with the DM 3 month group. The expression levels of VEGF, TNF‑α and IL‑1β in blood serum have been observed to exhibit similar expression change dynamics as those of the retina and vitreous. Therefore, these findings suggest that TL1A may be a protective factor of DR, and may provide a rationale for the development of novel therapeutic strategies to treat DR.

View Figures

View References

1	Ebneter A and Zinkernagel MS: Novelties in diabetic retinopathy. Endocr Dev. 31:84–96. 2016.PubMed/NCBI
2	Tarr JM, Kaul K, Chopra M, Kohner EM and Chibber R: Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013:3435602013. View Article : Google Scholar : PubMed/NCBI
3	Ahsan H: Diabetic retinopathy-biomolecules and multiple pathophysiology. Diabetes Metab Syndr. 9:51–54. 2014. View Article : Google Scholar : PubMed/NCBI
4	Cheung N, Mitchell P and Wong TY: Diabetic retinopathy. Lancet. 376:124–136. 2010. View Article : Google Scholar : PubMed/NCBI
5	Tang J and Kern TS: Inflammation in diabetic retinopathy. Prog Retin Eye Res. 30:343–358. 2011. View Article : Google Scholar : PubMed/NCBI
6	Hsu H and Viney JL: The tale of TL1A in inflammation. Mucosal Immunol. 4:368–370. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhang Z and Li LY: TNFSF15 Modulates neovascularization and inflammation. Cancer Microenviron. 5:237–247. 2012. View Article : Google Scholar : PubMed/NCBI
8	Sethi G, Sung B and Aggarwal BB: Therapeutic potential of VEGI/TL1A in autoimmunity and cancer. Adv Exp Med Biol. 647:207–215. 2009. View Article : Google Scholar : PubMed/NCBI
9	Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S and Li LY: A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J. 16:742–744. 2002.PubMed/NCBI
10	Parr C, Gan CH, Watkins G and Jiang WG: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis. 9:73–81. 2006. View Article : Google Scholar : PubMed/NCBI
11	Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL and Li LY: Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res. 89:1161–1167. 2001. View Article : Google Scholar : PubMed/NCBI
12	Qi JW, Qin TT, Xu LX, Zhang K, Yang GL, Li J, Xiao HY, Zhang ZS and Li LY: TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1. Proc Natl Acad Sci USA. 110:13863–13868. 2013. View Article : Google Scholar : PubMed/NCBI
13	Stefanini FR, Arevalo JF and Maia M: Bevacizumab for the management of diabetic macular edema. World J Diabetes. 4:19–26. 2013. View Article : Google Scholar : PubMed/NCBI
14	Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, Kuppermann B and Kenney M: Diabetic retinopathy and VEGF. Open Ophthalmol J. 7:4–10. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ho AC, Scott IU, Kim SJ, Brown GC, Brown MM, Ip MS and Recchia FM: Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: A report by the american academy of ophthalmology. Ophthalmology. 119:2179–2188. 2012. View Article : Google Scholar : PubMed/NCBI
16	Rao RC and Dlouhy BJ: Diabetic retinopathy. N Engl J Med. 367:1842012. View Article : Google Scholar : PubMed/NCBI
17	Deng W, Gu X, Lu Y, Gu C, Zheng Y, Zhang Z, Chen L, Yao Z and Li LY: Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization. Angiogenesis. 15:71–85. 2012. View Article : Google Scholar : PubMed/NCBI
18	Kim S and Zhang L: Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine. J Immunol Methods. 298:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kaul K, Hodgkinson A, Tarr JM, Kohner EM and Chibber R: Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diabetes Rev. 6:294–303. 2010. View Article : Google Scholar : PubMed/NCBI
20	Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW and Levison SW: Minocycline reduces proinflammatory cytokine expression, microglial activation and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 54:1559–1565. 2005. View Article : Google Scholar : PubMed/NCBI
21	Koleva-Georgieva DN, Sivkova NP and Terzieva D: Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv). 53:44–50. 2011.PubMed/NCBI
22	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press; Washington (DC): 2011, PubMed/NCBI
23	Zheng H, Zhang Z, Luo N, Liu Y, Chen Q and Yan H: Increased Th17 cells and IL17 in rats with traumatic optic neuropathy. Mol Med Rep. 10:1954–1958. 2014.PubMed/NCBI
24	Wang J, Chen S, Jiang F, You C, Mao C, Yu J, Han J, Zhang Z and Yan H: Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PLoS One. 9:e1105312014. View Article : Google Scholar : PubMed/NCBI
25	Antcliff RJ and Marshall J: The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 14:223–232. 1999. View Article : Google Scholar : PubMed/NCBI
26	Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, et al: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 13:181–189. 1999.PubMed/NCBI
27	Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, et al: Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer. 82:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
28	Hou W, Medynski D, Wu S, Lin X and Li LY: VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res. 11:5595–5602. 2005. View Article : Google Scholar : PubMed/NCBI
29	Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW and Hartnett ME: Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 27:331–371. 2008. View Article : Google Scholar : PubMed/NCBI
30	Zeng HY, Green WR and Tso MO: Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 126:227–232. 2008. View Article : Google Scholar : PubMed/NCBI
31	Wilkinson-Berka JL, Tan G, Jaworski K and Miller AG: Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res. 104:124–133. 2009. View Article : Google Scholar : PubMed/NCBI
32	Huang H, Gandhi JK, Zhong X, Wei Y, Gong J, Duh EJ and Vinores SA: TNFalpha is required for late BRB breakdown in diabetic retinopathy and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 52:1336–1344. 2011. View Article : Google Scholar : PubMed/NCBI
33	Burgós R, Simo R, Audí L, Mateo C, Mesa J, García-Ramírez M and Carrascosa A: Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 40:1107–1109. 1997. View Article : Google Scholar : PubMed/NCBI